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DOI 10.1016/j.ccr.2011.03.003SUMMARYAcquired resistance to ABL1 tyrosine kinase inhibitors (TKIs) through ABL1 kinase domain mutations, partic-
ularly the gatekeepermutant T315I, is a significant problem for patients with chronicmyeloid leukemia (CML).
Using structure-based drug design, we developed compounds that bind to residues (Arg386/Glu282) ABL1
uses to switch between inactive and active conformations. The lead ‘‘switch-control’’ inhibitor, DCC-2036,
potently inhibits both unphosphorylated and phosphorylated ABL1 by inducing a type II inactive conforma-
tion, and retains efficacy against the majority of clinically relevant CML-resistance mutants, including T315I.
DCC-2036 inhibits BCR-ABL1T315I-expressing cell lines, prolongs survival in mouse models of T315I mutant
CML and B-lymphoblastic leukemia, and inhibits primary patient leukemia cells expressing T315I in vitro and
in vivo, supporting its clinical development in TKI-resistant Ph+ leukemia.INTRODUCTION
Chronic myeloid leukemia (CML) and a subset of B cell acute
lymphoblastic leukemia (B-ALL) are characterized by the Phila-
delphia (Ph) chromosome and its product, the fusion tyrosine
kinase BCR-ABL1, which recapitulates CML-like myeloprolifera-
tive disease when expressed in hematopoietic stem cells in mice
(Daley et al., 1990). Motivated by this, imatinib, a small molecule
tyrosine kinase inhibitor (TKI) of ABL1, was developed for the
treatment of CML (Deininger and Druker, 2003). Structural
studies demonstrate that imatinib binds to the kinase domain
of ABL1 in an inactive conformation, referred to as the ‘‘DFG-
out’’ or type II conformation (Nagar et al., 2003; Schindler
et al., 2000), in which the ABL1 activation loop tyrosine 393 isSignificance
Kinase inhibitors have ushered in an era of targeted therapeu
ABL1 tyrosine kinase inhibitors (TKIs) such as imatinib are now
domain mutations is a significant problem, particularly the T
approved TKIs. DCC-2036 is an orally active TKI developed to
switching of ABL1 from inactive to active conformations. DC
models and in primary patient cells and represents a treatmen
Rational design of ‘‘switch-control’’ inhibitors is a promising str
556 Cancer Cell 19, 556–568, April 12, 2011 ª2011 Elsevier Inc.unphosphorylated and acts as pseudosubstrate to impair
access to the substrate pocket, whereas the ATP pocket is
blocked by the DFG Phe382. Such inactive kinase conforma-
tions provide unique binding pockets that are distinct from the
corresponding active (type I) conformations, and targeting of
these unique inactive conformations provides a general strategy
for designing selective kinase inhibitors (Huse andKuriyan, 2002)
that exploit additional binding sites adjacent to the ATP pocket
(Liu and Gray, 2006). The search for robust approaches for the
development of type II inhibitors remains an intense area of
research.
Imatinib induces durable hematologic and cytogenetic remis-
sions in the majority of patients with CML (Druker et al., 2006),
but a significant proportion eventually experience diseasetics in oncology. In chronic myeloid leukemia (CML), BCR-
standard treatment, but acquired resistance due to kinase
315I ‘‘gatekeeper’’ mutation that causes resistance to all
exploit evolutionarily conserved amino acids that regulate
C-2036 has efficacy against BCR-ABL1T315I in preclinical
t option for patients in whom conventional TKI therapy fails.
ategy for targeting the kinome in cancer and other diseases.
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Inhibition of BCR-ABL1 T315I by DCC-2036progression, frequently as a consequence of mutations in the
BCR-ABL1 kinase domain that render the enzyme resistant to
the drug (Gorre et al., 2001). To date, more than 50 different point
mutations in the ABL1 kinase domain have been detected in
imatinib-resistant patients (Shah et al., 2002), some of which
confer resistance by impairing the ‘‘induced fit’’ binding of
imatinib to the kinase domain (Roumiantsev et al., 2002). The
second generation BCR-ABL1 TKIs dasatinib (Shah et al.,
2004), nilotinib (Kantarjian et al., 2006), and bosutinib (Puttini
et al., 2006) inhibitmanyof theseBCR-ABL1mutants andprovide
clinical responses in imatinib-resistant CML. However, mutation
of the gatekeeper residue, threonine 315, to isoleucine (T315I)
causesvirtually absolute resistance toall fourTKIs, inpart through
steric interference with drug binding (Gorre et al., 2001). ABL1
mutations may also confer imatinib resistance by driving ABL1
toward the active conformation to which imatinib cannot bind
(Azam et al., 2003), which we refer to as conformational escape.
Interestingly, the T315I mutation has been shown to activate
c-ABL1 (Azam et al., 2008) by conformational escape through
stabilization of a ‘‘hydrophobic spine’’ that is a structural feature
shared by many activated kinases (Kornev et al., 2006). Confor-
mational escape may also underlie the resistance of secondary
mutants of the c-KIT kinase to imatinib and sunitinib in patients
with gastrointestinal stromal tumors (Gajiwala et al., 2009).
In CML, T315I accounts for 15% of the mutations recovered
frompatientswith imatinib resistancebut represents thepredom-
inant mechanism of acquired resistance to multiple TKIs (Shah
et al., 2007).Mutation of gatekeeper residues in epidermal growth
factor receptor and c-KIT also leads to resistance to TKIs,
including gefitinib and erlotinib in lung cancer (Pao et al., 2005),
and imatinib in gastrointestinal stromal tumors (Wardelmann
et al., 2005). Hence, the development of TKIs that retain potency
for gatekeeper mutants is of major clinical importance. Although
there are ongoing efforts to develop agents to treat CML with
the T315I BCR-ABL1 mutation, no drugs have yet won approval
for this indication. The aurora kinase inhibitors MK-0457 and
PHA-739358 inhibit T315I mutant BCR-ABL1 in vitro (Giles
et al., 2007;Gontarewicz et al., 2008), but hematologic responses
observed in clinical trials of these agents may be due predomi-
nantly to inhibition of Aurora kinase rather than BCR-ABL1
(Donato et al., 2010). AP-24534, a TKI that inhibits T315I BCR-
ABL1, has been described recently (O’Hare et al., 2009) and is
currently in clinical trials for the treatment of refractory CML.
We have approached the general problem of inhibitor resis-
tance, and specifically the issue of conformational escape resis-
tance, by using the concept of ‘‘switch control pocket’’ inhibition
to guide drug design (Flynn and Petillo, 2004). When a tyrosine
kinase adopts the active type I conformation, the transition is
promoted by specific ‘‘switch control’’ amino acids that interact
with and stabilize the phosphorylated activation loop tyrosine.
These switch-control residues adopt alternative orientations in
the inactive, unphosphorylated type II state. A switch-control
inhibitor is designed to interact with these residues in the inactive
conformation, providing a thermodynamic bias for stabilizing the
inhibitor-bound type II conformation, even in the face of phos-
phorylation or mutations that otherwise predispose escape of
the kinase to the type I active conformation. We refer to this
type of durable type II inhibition as conformational control
inhibition. Here, we report on structure-based design activitiesthat have culminated in the discovery and development of
DCC-2036, a conformational control inhibitor of ABL1, including
the BCR-ABL1T315I mutant.
RESULTS
Structure-Based Design of ABL1 Kinase Inhibitors
that Engage the Type II Conformation Glu282/Arg386
Salt Bridge
Although there is currently no reported structure of apo-ABL1 in
its active, phosphotyrosine 393 (pY393) type I conformation, the
structure of pY393-ABL1 in complex with dasatinib (Tokarski
et al., 2006) has been reported and shows that pY393 makes
binding interactions with both the catalytic loop arginine 362
(R362) and an activation loop arginine 386 (R386) (see Figure S1A
available online). The same R362 and R386 residues make elec-
trostatic interactions with Y393 in the active conformation
cocrystal structure of H396P ABL1 with VX-680 (Young et al.,
2006) Figure S1B), whereas in the structure of activated LCK
(Yamaguchi and Hendrickson, 1996), the homologous R363
and R387 residues also interact with the activation loop pY394.
Thus, in both ABL1 and LCK kinases, R386 or its homolog
R387 functions as a crucial conformational switch residue to
stabilize the activation loop phosphotyrosine in the active type
I state. When ABL1 is dephosphorylated and assumes the type
II inactive conformation, as inferred from the cocrystal structure
with imatinib (Nagar et al., 2003), the interaction between Y393
and R386 is disrupted: Y393 moves to occupy the substrate
pocket, whereas R386 moves to a unique inhibitor-accessible
region under the C helix in close proximity to E282 (Figure S1C).
Therefore, the E282/R386 amino acid pair provides a design
element for inhibitor binding to the inactive type II conformation
that is not available in the type I conformation.
To this end, several prototype diarylurea inhibitors were de-
signed, synthesized, and evaluated. From this effort, compounds
1and2were identified (Figures1Aand1B).Compound1contains
a tetrahydro-isoquinoline (THIQ) ring system wherein a basic
ring nitrogen was designed for hydrogen bonding to the acidic
ABL1 E282 residue, and a pendant carboxylic acid moiety (R =
CO2H) was included for hydrogen bonding to the basic ABL1
R386 residue. Compound 1 also contains a urea moiety to allow
a hydrogen bond with the conserved K271-E286 salt bridge of
ABL1, a t-butyl moiety to bind into the hydrophobic spine at the
third pocket position (Kornev et al., 2006), and a 2,3-dichloro-
phenyl ring to stabilize the DFG-phenylalanine F382 in the type
II-out conformation. Compound 1 exhibited an IC50 of 57 nM for
ABL1native and an IC50 of 773 nM for ABL1
T315I. Compound 2
replaced the THIQ ring with a quinoline ring, designed to
interact with E282 through an electrostatic interaction. Electro-
static potential calculations revealed that the C2 carbon of
the quinoline ring exhibits the highest partial positive charge (Fig-
ureS1D), focusing andorienting thepositive charge towardE282.
Compound 2 exhibited an IC50 of 140 nM for ABL1
native and an
IC50 of 711 nM for ABL1
T315I. Analogs of compounds 1 and 2
lacking the THIQ or the most distal nitrogen-containing portion
of the quinoline ring system were essentially inactive against
ABL1 (IC50 > 5 mM, Figure S1E), emphasizing the significance
of the E282/R386 switch-control residues as an inhibitor-
anchoring site.Cancer Cell 19, 556–568, April 12, 2011 ª2011 Elsevier Inc. 557
A B C
D E
Compound 1  (R = CO H)
E282/R386 switch binder
ABL1 = 57 nM
T315I ABL1 = 773 nM
2 Compound 2
E282/R386 switch binder
ABL1 = 140 nM
T315I ABL1 = 711 nM
Compound 3 
ATP hinge binder
ABL1 = 88 nM
T315I ABL1 = 80 nM
Compound 4 
E282/R386 switch + ATP hinge binder
ABL1 = 9 nM
T315I ABL1 = 17 nM
DCC-2036 
E282/R386 switch + ATP hinge binder
ABL1 = 0.8 nM
T315I ABL1 = 4 nM
Figure 1. Structures of Switch-Control Inhibitors of ABL1 Kinase
(A) Compound 1 contains a THIQ ring nitrogen that interacts with switch control amino acid E282, a pendant carboxylic acid moiety that interacts with switch
control amino acid R386, a t-butyl moiety to bind into the hydrophobic spine position No. 3 pocket, and a 2,3-dichlorophenyl ring to bind into the extended
hydrophobic pocket of ABL1.
(B) Compound 2 replaces the THIQ ring with a quinoline ring.
(C) Compound 3 contains a pyridine ring nitrogen and a pendant carboxamide-NH moiety to form hydrogen bonds with M318 at the ATP hinge.
(D) Compound 4 incorporates the THIQ ring of compound 1 and the carboxamide containing pyridine ring of compound 3.
(E) DCC-2036 incorporates the quinoline ring of compound 2 and the carboxamide containing pyridine ring of compound 3. The IC50 of each compound for
inhibition of the kinase domains of purified ABL1native and ABL1T315I (see Experimental Procedures) is indicated.
See also Figure S1 and Table S1.
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Inhibition of BCR-ABL1 T315I by DCC-2036To confirm the mode of binding of compound 1, an X-ray
crystal structure was obtained in complex with the ABL1native
kinase domain (Figure S1F). This structure revealed that the
THIQ ring system of compound 1 does indeed bind to the
E282/R386 switch-control residues, with the THIQ ring basic
nitrogen and carboxylic acid moiety making hydrogen bond
interactions with the acidic side chain of E282 (3.26 A˚) and the
guanidinyl side chain of R386 (3.32 A˚), respectively. Other
features of inhibitor binding include hydrogen bond formation
between the urea moiety and the K271-E286 salt bridge, binding
of the t-butyl moiety into the third pocket of the hydrophobic
spine, and orientation of the 2,3-dichlorophenyl ring to stabilize
F382 in an edge-facep-interaction. The key bonding interactions
between compound 1 and ABL1native are summarized in Table
S1. It is noteworthy that this binding mode affords a 57 nM inhib-
itor of ABL1 kinase without relying on binding into the ATP
pocket-hinge region, a typical requirement of classical type II
and ATP-competitive type I inhibitors.
Design of Dual-Anchoring Inhibitors of ABL1 that Bind
Both the Glu282/Arg386 Switch Pair and the ATP
Pocket-Hinge Met318
To improve potency we next designed inhibitors that provided
dual-docking sites to both the switch control pocket E282/R386558 Cancer Cell 19, 556–568, April 12, 2011 ª2011 Elsevier Inc.pair and also to the ATP hinge, reasoning that such a dual-
anchoring inhibitor might provide the increased binding energy
required to stabilize oncogenic and resistant forms of ABL1 in
the type II conformation. To probe docking of inhibitor only to
the ATP hinge region, we prepared compound 3 (Figure 1C),
which contains a carboxamide-substituted pyridine ring to form
hydrogen bonds with the backbone of the ATP hinge residue
M318. However, compound 3 does not extend in the direction
of the activation loop to engage the switch-control E282/
R386 residues. Compound 3 exhibited an IC50 of 88 nM versus
ABL1native, similar in potency to compounds 1 and 2, indicating
that either inhibitor-anchoring mode affords similar potency.
We then combined both E282/R386 switch-control binding
and M318-ATP hinge-binding moieties by synthesizing
compound 4 (Figure 1D), and DCC-2036 (Figure 1E). Compound
4 and DCC-2036 exhibited IC50 values of 9 nM and 0.8 versus
ABL1native, respectively. Significantly, these dual-anchoring
inhibitors also showed potent inhibition of the gatekeepermutant
ABL1T315I, with IC50 values of 17 and 4 nM, respectively. Thus,
incorporation of the additional switch control pocket-binding
quinoline ring in DCC-2036 leads to a 100-fold improvement in
potency versus ABL1native and a 20-fold improvement in potency
versus gatekeeper mutant ABL1T315I, compared to the proto-
typic type II compound 3.
Figure 2. Cocrystal Structure of DCC-2036 Bound to ABL1T315I Kinase
(A) Ribbon diagram of the type II conformation of ABL1T315I in complex with DCC-2036. Note the trajectory of the quinoline C2 carbon oriented toward E282
(d = 3.30 A˚). The activation-loop internal switch (green) is in the ‘‘off state,’’ with F382 occluding the ATP pocket and Y393 occluding the substrate-binding pocket,
making a hydrogen bond with D363. DCC-2036 makes additional hydrogen bonds with E286 (2.80 and 2.90 A˚), and with the ATP hinge-residue M318 (2.95 and
3.18 A˚). Key hydrogen bonds and electrostatic interactions are highlighted as dashed lines.
(B) View of the DCC-2036/ABL1T315I complex. The activating hydrophobic spine is disrupted by displacement of F382. DCC-2036 makes stabilizing interactions
with spine residues M290, H361, and the displaced residue F382. DCC-2036 (t-Bu moiety) occupies the third position in this ‘‘inhibitory’’ hydrophobic spine. Key
interactions of the inhibitor quinoline ring with the E282/R386 switch pair are also shown.
See also Figure S2, and Tables S1 and S2.
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Inhibition of BCR-ABL1 T315I by DCC-2036Structure of DCC-2036 Bound to ABL1native
and Gatekeeper Mutant ABL1T315I
Cocrystal structures of DCC-2036 with ABL1native (Figure S2A)
and with ABL1T315I (Figure 2A; Figure S2B) were solved
(Table S2). In both structures, DCC-2036 binds to the DFG-out
type II conformation. Similar to compound 1, the quinoline ring
of DCC-2036 forms an electrostatic interaction with E282
(d = 4.06 A˚ in ABL1native, 3.30 A˚ in ABL1T315I; Table S1). In the
ABL1native structure, E282 is held in place to retain a hydrogen
bond with R386 (d = 2.76 A˚). The urea nitrogens form two
hydrogen bonds with the conserved K271-E286 salt bridge,
with an additional hydrogen bond formed between the urea
carbonyl and the backbone amino group of D381. The t-butyl
moiety binds into the hydrophobic spine pocket, thereby forcing
the DFG F382 (yellow) out into the mouth of the ATP pocket, and
the carboxamide-substituted pyridine ring forms two hydrogen
bonds with the ATP hinge residueM318. The fluorine substituent
on the central phenyl ring is positioned ortho- to the urea moiety,
providing stereoelectronic bias for inducing planarity of the
fluoro-phenyl ring and the urea function. Such stereoelectronic
restriction optimally orients the phenyl ring for p-interaction
with F382.
Recently, an activating hydrophobic spine of ABL1T315I has
been described (Azam et al., 2008), wherein a vertical cluster
of hydrophobic amino acids stabilizes the type I active state.
This hydrophobic cluster includes L301, M290, F382, H331,
and the additional mutant I315 as a fifth reinforcing hydrophobic
residue further stabilizing the type I active state (Modugno et al.,
2007) (Figure S2C). In the cocrystal structure of DCC-2036 with
ABL1T315I, this activating spine has been disrupted by outward
movement of F382 (Figure 2B), which is stabilized by the central
2-fluoro-phenyl ring of DCC-2036. The inhibitor also makes
productive hydrophobic contact with the mutant gatekeeperI315 and spine residues M290 and H361, whereas the t-butyl
residue of DCC-2036 occupies the third position of the hydro-
phobic spine as a surrogate of F382, effectively establishing an
inhibitory hydrophobic spine in the interior of the kinase, which
includes L301, M290, the inhibitor (DCC-2036 t-butyl moiety),
and H361 (Figure 2B).
DCC-2036 Inhibits Unphosphorylated ABL1native,
Phospho-ABL1native, ABL1H396P, and ABL1T315I
in a Non-ATP-Competitive Manner
To investigate the biochemical mechanism of ABL1 inhibition
by DCC-2036, we compared the inhibitory activity of DCC-
2036 to that of imatinib, dasatinib, and nilotinib (Table 1) against
purified native ABL1 in unphosphorylated (u-ABL1native) and
phosphorylated (p-ABL1native) forms, unphosphorylated and
phosphorylated gatekeeper mutant ABL1T315I, and the
activation loop mutant ABL1H396P. Consistent with the structural
data in Figure S2A, DCC-2036 potently (IC50 0.82 nM) inhibited
u-ABL1native, which is thought to exist predominantly in the
inactive type II conformation. In addition, DCC-2036 also
strongly inhibited p-ABL1native (IC50 2 nM), which more readily
adopts an active, type I conformation. More significantly,
DCC-2036 potently inhibited both u-ABL1T315I (IC50 5 nM)
and p-ABL1T315I (IC50 4 nM), both of which exist predominately
in the type I conformation due to stabilization of an activating
hydrophobic spine by the T315I mutation (Azam et al., 2008).
DCC-2036 also potently inhibited ABL1H396P (IC50 1.4 nM),
which, like ABL1T315I, is predisposed to exist predominately in
a type I activated conformation due to the restricted backbone
torsional angles imposed by the mutant Pro396 (Young et al.,
2006). Together, these results argue that DCC-2036 can
effectively inhibit forms of ABL1 predisposed to adopt active,
DFG-in conformations by forcing the kinase domains intoCancer Cell 19, 556–568, April 12, 2011 ª2011 Elsevier Inc. 559
Table 1. Inhibition (IC50, nM) of ABL1 Kinases by DCC-2036 and Other TKIs
u-ABL1native p-ABL1native ABL1H396P u-ABL1T315I p-ABL1T315I
DCC-2036 0.75 ± 0.11 2 ± 1 1.4 ± 0.1 5 ± 1 4 ± 1
Imatinib 75 ± 3 7,700 ± 1,000 3,000 ± 1,000 >10,000 >10,000
Dasatinib 1.1 ± 0.1 0.7 ± 0.4 0.5 ± 0.1 >10,000 >10,000
Nilotinib 0.87 ± 0.09 2.2 ± 1.2 1.1 ± 0.3 >5,000 3,800 ± 1,200
IC50 values (mean ± SD) were determined as described in Experimental Procedures. See also Tables S3 and S4.
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Inhibition of BCR-ABL1 T315I by DCC-2036inhibitor-bound, inactive type II conformations. By comparison,
imatinib had moderate inhibitory activity only for u-ABL1native
(IC50 75 nM) while losing significant potency for those forms
that are predisposed to exist predominately in the ‘‘switch on’’
activated conformation (p-ABL1native, ABL1H396P, and
ABL1T315I). As previously reported (Shah et al., 2004; Weisberg
et al., 2006), dasatinib and nilotinib retained potency for
p-ABL1native and ABL1H396P but were essentially inactive against
mutant ABL1T315I (IC50 > 10,000 and 3,800 nM, respectively).DCC-2036 Inhibits ABL1 Kinase in a Non-ATP-
Competitive Manner and Exhibits Prolonged Kinase
Residency Time
For ATP competitive inhibitors such as imatinib, an increase of
ATP concentration can result in significant loss of inhibitor
potency. However, DCC-2036 lost little activity against AblT315I,
even in the presence of high (5 mM) ATP concentrations that are
typical of the intracellular milieu (Table S3). DCC-2036 exhibited
very prolonged dissociation rate constants (koff) from its complex
with all three ABL1 forms (Table S4). The koff value of 0.00172
min1 for p-ABL1native corresponds to a t1/2 value of 402 min,
demonstrating that DCC-2036, once bound, exhibits prolonged
residency time in complex with ABL1. This dissociation rate
constant is considerably longer than the respective values ob-
tained for dasatinib (153 min) and nilotinib (180 min).Table 2. Kinase Inhibition Profile of DCC-2036
Kinase IC50 (nM)
ABL1 0.75 ± 0.11Kinase Inhibition Profile of DCC-2036
In addition to ABL1, DCC-2036 also inhibited the SRC family
kinases SRC, LYN, FGR, and HCK, and the receptor TKs KDR,
FLT3, and TIE2 (Table 2). Notably, DCC-2036 spared c-KIT
(IC50 481 nM). DCC-2036 was further evaluated against a broad
panel of human kinases but did not inhibit a significant number of
kinases outside this ensemble (Table S5).
SRC 34 ± 6
LYN 29 ± 1
FGR 38 ± 1
HCK 40 ± 1
KDR 4 ± 0.3
FLT3 2 ± 0.3
TIE2 6 ± 0.3
c-KIT 481 ± 57
PDGFRa 70 ± 10
PDGFRb 113 ± 10
Aurora A >5000
CDK2/Cyclin D >5000
IC50 values (mean ± SD) were determined as described in Experimental
Procedures versus purified kinase domains. See also Table S5.DCC-2036 Inhibits Cellular Proliferation of Ba/F3 Cells
Expressing Native or Mutant BCR-ABL1
We next tested the ability of DCC-2036 to inhibit proliferation of
Ba/F3cells transformed to IL-3 independencebyBCR-ABL1native
or a series of TKI-resistant BCR-ABL1 mutants arising in the P
loop, the interior N-lobe, the E helix proximal to the catalytic
loop, the catalytic loop, the activation loop, and the hinge/
gatekeeper region (Table 3). Similar to imatinib, dasatinib, and ni-
lotinib, DCC-2036 effectively inhibited the proliferation of Ba/F3
cells expressing native BCR-ABL1native (IC50 5.4 nM), but DCC-
2036 also retained potency against Ba/F3 cells expressing
BCR-ABL1 mutants that are resistant to imatinib, dasatinib
(T315A), and nilotinib (L248R, Y253H, E255V, F359C), as well
as the gatekeeper mutant BCR-ABL1T315I (IC50 13 nM), where560 Cancer Cell 19, 556–568, April 12, 2011 ª2011 Elsevier Inc.all three FDA-approved TKIs were ineffective. DCC-2036 also in-
hibited proliferation of the Ph+ cell line K562 (IC50 5.5 nM), and
induced apoptosis in both BCR-ABL1-expressing Ba/F3 and
K562 cells at nanomolar concentrations (data not shown). Impor-
tantly, the growth of parental Ba/F3 cells (in the presence of IL-3)
was not appreciably inhibited by DCC-2036 until concentrations
exceeded 3 mM, demonstrating that the drug is not generally
cytotoxic. By contrast the dual Aurora A/ABL1 kinase inhibitor
MK-0457 did not discriminate between parental and BCR-
ABL1-transformed Ba/F3 cells, indicative of global cytostatic
activity (Table 3). In addition to the T315I mutant, DCC-2036
also inhibited proliferation of several common TKI-resistant
mutants of BCR-ABL1, including G250E, Q252H, Y235F,
E255K, V299L, F317L, and M351T, at IC50 values ranging from
6 to 150 nM (Table 3). Collectively, these mutants mediate the
majority of clinical TKI resistance in patients with CML (O’Hare
et al., 2009; Shah et al., 2002).DCC-2036 Inhibits Mutant BCR-ABL1T315I Signaling and
Prolongs Survival in a Mouse Ba/F3 Cell Allograft Model
We examined the ability of DCC-2036 to inhibit the phosphoryla-
tion of BCR-ABL1 and its downstream targets STAT5 andCrkL in
transformed Ba/F3 cells (Figure 3A). At concentrations that
correlated with its cytotoxic effects, DCC-2036 effectively in-
hibited autophosphorylation of BCR-ABL1native (IC50 29 nM)
and BCR-ABL1T315I (IC50 18 nM), as well as the phosphorylation
of STAT5 in both cell lines (IC50 28 and 13 nM, respectively).
Phosphorylation of the BCR-ABL1 substrate CrkL was also
Table 3. Comparison of Inhibition of Cellular Proliferation
by ABL1 TKIs (IC50, nM)
Ba/F3-BCR-ABL1 DCC-2036 Imatinib Dasatinib Nilotinib MK-0457
Ba/F3 Parenta 3,500 >10,000 3,800 9,500 102
Native 5.4 48 0.4 2.1 104
L248R 51 >10,000 7.3 930 110
G250E 98 1,900 2.8 67 180
Q252H 24 700 0.3 5.1 130
Y253F 39 2,300 2 63 80
Y253H 56 >10,000 1 120 190
E255K 127 6,400 8 80 84
E255V 150 >10,000 2 95 190
V299L 6 190 8 10 200
T315A 19 536 65 17 88
T315I 13 >10,000 5,200 2,800 74
F317L 36 417 2.3 10 84
M351T 14 417 1.1 4.2 65
F359C 120 2,500 2.7 190 130
H396P 81 1,700 1.2 49 160
IC50 values were determined as described in Experimental Procedures.
aDetermined in the presence of 10 ng/ml IL-3.
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Inhibition of BCR-ABL1 T315I by DCC-2036inhibited, although to a lesser extent, in both cell lines (BCR-
ABL1native IC50 495 nM; BCR-ABL1
T315I IC50 2600 nM). Im-
portantly, imatinib, dasatinib, and nilotinib all failed to inhibit
phosphorylation of BCR-ABL1, STAT5, and CrkL in Ba/F3 cells
expressing BCR-ABL1T315I (IC50 values >5 mM; data not shown).
BCR-ABL1-transformed Ba/F3 cells can efficiently engraft
syngeneic Balb/c mice following intravenous injection (Ilaria
and Van Etten, 1995), proliferating in blood, marrow, and spleen,
and eventually causing morbidity and death of the recipients.
A single oral dose of DCC-2036 at 100 mg/kg afforded circu-
lating plasma levels that exceeded 12 mM for up to 24 hr (data
not shown), and effectively inhibited BCR-ABL1 signaling for
up to 8 hr in Ba/F3- BCR-ABL1T315I leukemia cells isolated
from bone marrow (BM) and spleen of tumor-bearing mice, as
assessed by intracellular flow cytometric staining for phospho-
STAT5 (Figure 3B) and immunoblotting of tissue extracts for
phospho-BCR-ABL1 and phospho-STAT5 (Figure 3C). Treat-
ment of mice bearing Ba/F3- BCR-ABL1T315I leukemia cells
with DCC-2036 at 100 mg/kg once daily by oral gavage signifi-
cantly prolonged their survival, whereas imatinib at 100 mg/kg
twice daily was ineffective (Figure 3D). In this aggressive allograft
model, DCC-2036 was as effective for treatment of BCR-
ABLT315I leukemia as imatinib at 100 mg/kg twice daily was for
treatment of BCR-ABL1native leukemia, and reduced the
leukemia cell burden in the spleens of treated mice (Figure 3E).DCC-2036 Demonstrates Efficacy in Retroviral
Transduction/Transplantation Mouse Models
of BCR-ABL1T315I CML and Ph+ B-ALL
To extend these results to primary myeloid and lymphoid leuke-
mias induced by BCR-ABL1, we employed a well-characterized
retroviral BM transduction/transplantation model system. When
BM from 5-fluorouracil (5-FU)-treated donors is transduced withBCR-ABL1 retrovirus and transplanted intravenously into irradi-
ated mice, recipients develop an aggressive and fatal CML-like
myeloproliferative neoplasm (MPN), characterized by massive
expansion of and extensive organ infiltration by maturing
myeloid cells (Li et al., 1999). The CML-like MPN arises from
hematopoietic stem cells (Hu et al., 2006), and is transplantable
(Li et al., 1999) and responsive to TKI therapy (Hu et al., 2004).
When donors are not treated with 5-FU, recipients of BCR-
ABL1-transduced BM instead develop aggressive precursor B
cell acute lymphoblastic leukemia/lymphoma (B-ALL), arising
from early lymphoid progenitors (Hu et al., 2006) and character-
ized by involvement of the BM, spleen, lymphatics, and pleural
cavity (Li et al., 1999).
In the CML model, treatment of recipients of BCR-ABL1T315I-
transduced BM with DCC-2036 at 100 mg/kg once daily signifi-
cantly prolonged their survival from a median of 20 to 32 days
(Figure 4A), and was associated with an improvement in the
circulating leukocyte counts in treated mice (Figure 4B). In
BCR-ABL1-induced B-ALL, genetic studies in mice have impli-
cated SRC family kinases in the disease pathogenesis (Hu
et al., 2004), suggesting that the inhibitory activity of DCC-
2036 toward LYN, FGR, and HCK (Table 2) might be of thera-
peutic benefit in this disease. Indeed, a previous report
suggested that dasatinib, which also inhibits SRC kinases, has
therapeutic activity against B-ALL induced by T315I BCR-
ABL1 in mice (Hu et al., 2006). Accordingly, we also compared
the activity of DCC-2036 against imatinib and dasatinib in mice
with B-ALL induced by BCR-ABL1T315I. DCC-2036 had efficacy
that was superior to both imatinib and dasatinib (Figure 4C),
significantly prolonging the survival of treated mice (median
survival 47 days), although all mice in this cohort eventually
succumbed to B-ALL. Interestingly, we noted that the histopa-
thology of the B-lymphoid leukemia/lymphoma appeared to be
altered in DCC-2036-treated mice. Rather than developing the
malignant hemorrhagic pleural effusion that was the predomi-
nant cause of death in the other three cohorts, the majority (ten
of 14) of DCC-2036-treated recipients had absent or minimal
(<0.1ml) pleural effusions, but instead developed hindlimb paral-
ysis due to lymphomatous involvement of vertebral spinal cord
(data not shown). This suggests that effective treatment of
disease outside the central nervous system by DCC-2036 might
have altered the natural history of the leukemia and selected for
malignant cells residing in a privileged site. Together, these
results demonstrate that oral DCC-2036 has efficacy against
primary myeloid and lymphoid leukemias induced by BCR-
ABL1T315I in mice.
DCC-2036 Inhibits BCR-ABL1, Including the T315I
Mutant, in Primary Patient Cells In Vitro and In Vivo
We tested the ability of DCC-2036 to inhibit myeloid colony
formation from BMmononuclear cells from a patient with newly-
diagnosed chronic-phase CML, and a patient with relapsed
CML in accelerated phase who was intolerant of imatinib.
DCC-2036 inhibited the formation of myeloid colonies in a
concentration-dependent manner that was equivalent to
clinically relevant concentrations of imatinib (Figure 5A). Im-
portantly, DCC-2036 had minimal toxicity to normal hematopoi-
etic colony-forming cells at concentrations up to 2000 nM
(Figure 5A; data not shown). In leukemic blasts from a patientCancer Cell 19, 556–568, April 12, 2011 ª2011 Elsevier Inc. 561
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Figure 3. DCC-2036 Inhibits BCR-ABL1 Signaling in Ba/F3 Cells In Vitro and in a Mouse Allograft Model
(A) Inhibition of BCR-ABL1 signaling in Ba/F3 cells expressing BCR-ABL1native (top panel) or BCR-ABL1T315I (bottom panel) by different concentrations of
DCC-2036. (B) Complete and sustained inhibition of pSTAT5 in mice bearing Ba/F3-BCR-ABL1T315I leukemia cells following a single oral dose of DCC-2036 at
100 mg/kg. At the indicated time after the dose, mice were sacrificed, and the level of phosphorylation of STAT5 was assessed in leukemic (GFP+) cells by
intracellular staining with anti-pSTAT5 antibody and flow cytometric analysis. The gray histogram represents the level of STAT5 activation prior to the dose,
whereas the pink curve is from parental Ba/F3 cells starved of IL-3 and serum, representing baseline STAT5 activation.
(C) Immunoblot analysis of phospho-BCR-ABL1T315I and phospho-STAT5 levels in spleen tissue extracts from the experiment in (B). Note that due to contri-
butions from nonleukemic cells, the extent of pSTAT5 inhibition is not as great as in (B).
(D) Survival curve of cohorts of mice injected on day 0 with 106 Ba/F3 cells expressing either BCR-ABL1native or BCR-ABL1T315I, and treated beginning on day 3
with either imatinib at 100 mg/kg twice daily or DCC-2036 at 100 mg/kg once daily by oral gavage. The survival of the T315I DCC-2036-treated cohort was
significantly longer than either the T315I imatinib-treated or vehicle-treated cohorts (p < 0.0001, Wilcoxon test).
(E) Box-style plot of spleen weights (mg) from Ba/F3-BCR-ABL1T315I leukemia-bearing mice treated with vehicle or DCC-2036, assessed at the time of morbidity
or death. The difference in spleen weight of the DCC-2036-treated and the vehicle-treated cohorts was of borderline significance (p = 0.06, Student’s unpaired
t test).
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Figure 4. DCC-2036 Has Efficacy in Mouse Models of CML and Ph+ B-ALL
(A) Survival curve for recipients of 5-FU-treated BM transduced with BCR-ABL1T315I retrovirus, treated by oral gavage beginning at day 5 posttransplant with
vehicle (red line, n = 10), or DCC-2036 at 100 mg/kg once daily (green line, n = 14). All recipient mice succumbed to CML-like MPN. The difference in survival
between the two cohorts is significant (p = 0.007, Wilcoxon test).
(B) Scatter plot of peripheral blood leukocyte counts versus time from the cohorts in (A). Red squares represent individual vehicle-treated mice, whereas green
circles represent individual DCC-2036-treated mice. The difference in mean leukocyte counts on day 20 between DCC-2036- and vehicle-treated cohorts was
significant (p = 0.0002, Student’s unpaired t test).
(C) Survival curve for Balb/c recipients of non-5-FU-treated BM transduced with BCR-ABL1T315I retrovirus, treated by oral gavage beginning at day 10 post-
transplant with vehicle (red line, n = 6), imatinib at 100 mg/kg once daily (black line, n = 7), dasatinib at 10 mg/kg twice daily (blue line, n = 10), or DCC-2036 at
60 mg/kg twice daily (green line, n = 14). The survival of the DCC-2036-treated cohort was significantly prolonged (Wilcoxon tests) compared to cohorts treated
with vehicle (p = 0.0184), imatinib (p = 0.0474), and dasatinib (p < 0.0001).
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Inhibition of BCR-ABL1 T315I by DCC-2036with relapsed/refractory Ph+ B-ALL with the T315I mutation,
DCC-2036 inhibited phosphorylation of BCR-ABL1, STAT5,
and CrkL (Figure 5B) and decreased cell viability in vitro (Fig-
ure S3A). DCC-2036 also inhibited phosphorylation of CrkL in
primary leukemia cells from a patient with chronic-phase CML
and L298V mutation (Figure 5B).
Based on these preclinical results, DCC-2036 has been
advanced to a phase 1 clinical trial in patients with Ph+ leukemia
that has relapsed or been refractory to at least two of the FDA-
approved TKIs (http://www.ClinicalTrials.gov, identifier
NCT00827138). In a patient with CML chronic phase and the
T315I mutation who received DCC-2036 (tosylate salt) at
a 300 mg dose level, we observed significant (65%) suppres-
sion of STAT5 phosphorylation in peripheral blood leukemia cells
that was maximum about 2 hr following the initial day 1 dose,
with more sustained inhibition observed following 1 week of
continuous daily dosing (Figure S3B). In two additional patients,
significant inhibition of CrkL phosphorylation in circulatingleukemic cells was observed in the first cycle of treatment,
with sustained inhibition apparent in the second week of therapy
(Figure 5C). Together, these results demonstrate that DCC-2036
is capable of suppressing BCR-ABL1 activity in primary
leukemic cells, both in vitro and in vivo, from patients with Ph+
leukemia who are refractory to multiple TKIs, including those
with the T315I mutation.DISCUSSION
Kinases are involved in a broad range of essential cellular func-
tions, and are regulated in vivo by adopting different conforma-
tions. Disruption of kinase conformational regulation through
protein fusions, deletions, or missense mutations can lead to
pathologic conditions, including cancer. We have initiated
a broad-based approach to kinase inhibition through identifica-
tion of key amino acid residues that are critical for the fluxingCancer Cell 19, 556–568, April 12, 2011 ª2011 Elsevier Inc. 563
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Figure 5. DCC-2036 Inhibits BCR-ABL1 in Patient Leukemic Cells In Vitro and In Vivo
(A) Inhibition of BM-derived myeloid colonies (mean + SD) from a patient with newly diagnosed CML in chronic phase (left panel), a patient with relapsed CML in
accelerated phase whowas intolerant of imatinib (middle panel), and a normal individual (right panel). In the left andmiddle panels, the differences between any of
the drug-treated cultures and untreatedwere significant (p < 0.001, Student’s t test), whereas none of the differences in the right panel was statistically significant.
(B) InhibitionofBCR-ABL1kinaseactivityandsignalingbyDCC-2036 in leukemicblasts frompatients in vitro. Left panel showspatientwithPh+B-ALLand theT315I
mutation, which had an allele frequency of 40% estimated from DNA-sequencing data. The relative levels of phospho-BCR-ABL1T315I, phospho-STAT5, and
phospho-CrkL versus untreated are shown. Note that this patient expressed the p190 isoform of BCR-ABL1T315I. Right panel shows patient with CP-CML and
aL298Vmutation.PB leukocyteswere incubated for 3hrwith the indicatedconcentrationsofDCC-2036, andCrkLphosphorylationwasquantitatedby immunoblot
analysis of quadruplicate blots. Data (mean normalized pCrkL ± SD) were fitted to a sigmoidal curve (GraphPad Prism), and an IC50 value was calculated.
(C) Pharmacodynamic analysis of inhibition of CrkL phosphorylation by DCC-2036 (tosylate salt in formulated tablets, 100 mg BID dose level) in circulating CML
cells in vivo obtained on days 1 and 8 of cycle 1 of treatment in a phase 1 clinical trial. Left panel shows patient with CML chronic phase and V299L mutation
(note that on day 8, samples before and 0.5–2 hr after dosing were not obtained). Right panel shows patient with CML accelerated phase and no detectable BCR-
ABL1 mutation. pCrkL levels (mean + SD) normalized to percentage of day 1 predose level are shown below.
See also Figure S3.
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Inhibition of BCR-ABL1 T315I by DCC-2036of kinases between conformational states, and the design of
inhibitors that bind to such residues.
In ABL1, R386 is a critical anchoring partner for stabilizing
pY393 in the active conformation. In the inactive type II confor-
mation, R386 and Y393 separate from each other, with Y393
moving to occupy the substrate pocket, and R386 shifting to
the interior of the kinase toward E282 (Figure S1C). This alterna-
tive disposition of E282/R386 provides a basis for rational inhib-
itor design. Here, we have demonstrated the utility of this E282/
R386 anchor for design of ABL1 inhibitors, culminating in the
discovery of DCC-2036. Prototype inhibitor compounds 1 and
2 (Figure 1), which orient a THIQ or quinoline basic ring system
toward the E282-R386 inhibitory anchor, exhibited potencies in
the 57–140 nM range for ABL1native, whereas close structural
analogs lacking functionality for interaction with E282 or R386
were inactive (Figure S1E). It is noteworthy that this level of
inhibition, which is equivalent to the potency of imatinib for
ABL1native, is achieved without extending inhibitor binding into
the ATP hinge region. Additionally, compounds 1 and 2 also
exhibit potencies in the 700 nM range for the gatekeeper mutant
ABL1T315I. A similar level of potency was realized by compound
3, which anchors into the ATP hinge but does not extend to the
switch E282-R386 salt bridge.
Combining both an ATP hinge-binding anchor and an E282/
R386 binding anchor within a single inhibitor led to compound
4 and DCC-2036, which exhibit much greater potency versus
ABL1native (IC50 of 9 and 0.8 nM, respectively) and against mutant
ABL1T315I (17 and 4 nM, respectively). Although compound 3 is
equipotent against ABL1native and ABL1T315I and must therefore
avoid steric clash with substitutions at the gatekeeper residue,
the ability to bind both the ATP hinge and the switch-control
regions is what affords DCC-2036 the potency (100-fold
decrease in ABL1native IC50 versus compound 3) required for
a clinical drug candidate. A derivative of DCC-2036 lacking the
2-fluorine substituent on the phenyl ring maintained full potency
for inhibiting ABL1native and ABL1T315I (IC50 1 and 7 nM, respec-
tively), demonstrating that the orientation of this fluorine is not
critical for inhibition of the gatekeeper mutant by DCC-2036
(data not shown). The structure of DCC-2036 with u-ABL1native
also revealed an ideal hydrogen bond (2.76 A˚) between the
carboxylate side chain of E282 and the guanidinium side chain
of R386. We speculate that this type II switch state E282/R386
hydrogen bond induced by DCC-2036 contributes to its high
potency versus u-ABL1native (IC50 0.8 nM).
DCC-2036’s mode of binding provides a durable mode of type
II inhibition that affords a prolonged dissociation rate constant,
resiliency to high ATP concentrations, and overcomes the clin-
ical problem of conformational escape resistance by making
interactions within the type II state (Figure 2A) that override the
effect of point mutations that drive ABL1 toward the active
type I state. We refer to this type of inhibition as conformational
control inhibition. DCC-2036 inhibits both ABL1T315I and
ABL1H396P (IC50 values of 4 and 1.4 nM, respectively), which
are known to exist predominantly in the type I active conforma-
tion (Azam et al., 2008; Young et al., 2006). Structural data (Fig-
ure 2B) suggest that DCC-2036 may, in part, lead to conforma-
tional control of ABL1 by invoking an inhibitor-participating
hydrophobic spine (Azam et al., 2008; Kornev et al., 2006) in
which a portion of DCC-2036 substitutes for phenylalanine inthe third spine position while also making interactions with the
second and fourth spine residues, M290 and H361 (Figure 2B).
DCC-2036 exhibits high potency against cell lines expressing
mutant forms of BCR-ABL1, including T315I and H396P, that
collectively account for more than 85% of TKI-resistant patients
with CML in whom ABL1 kinase mutations are identified (Shah
et al., 2002, 2007). ABL1 mutants involving the P loop residue
E255 (E255V/K) were relatively less sensitive to DCC-2036 (Table
3), and are also refractory to the type II inhibitors imatinib and ni-
lotinib. In the native ABL1 structure, the acidic side chain of E255
makes an electrostatic interaction with a lysine residue on the
other arm of the loop, and disruption of this interaction might
distort the nearby ATP hinge region into which DCC-2036 binds.
A Ba/F3 cell-based mutagenesis screen for resistance to DCC-
2036 recovered no BCR-ABL1 mutations at higher drug concen-
trations, whereas mutations at Y253 and E255 emerged at lower
concentrations (T. O’Hare, personal communication). However,
pharmacokinetic data from the phase 1 clinical trial have demon-
strated that DCC-2036 can achieve plasma levels well above
these concentrations (data not shown). To our knowledge, there
were no mutations recovered that are known to destabilize the
inactive conformation of BCR-ABL1 toward its active, type I
conformation (Azam et al., 2003; Sherbenou et al., 2010), nor
were there mutations identified in the switch control amino acids
E282/R386, which may be required for assembly of the catalyti-
cally active state (Kornev et al., 2006). Together, these observa-
tions suggest that acquired resistance to DCC-2036 therapy in
CML may be less frequent than for the three ATP-competitive
ABL1 inhibitors in current clinical use.
DCC-2036 inhibits BCR-ABL1, STAT5, andCrkL phosphoryla-
tion in BCR-ABL1-expressing cells. In a Ba/F3 cell allograft
model, oral administration of DCC-2036 resulted in sustained
inhibition of phosphorylation of both BCR-ABL1T315I and
STAT5, a significant reduction in leukemic burden, and pro-
longed survival (Figure 3). Oral administration of DCC-2036 at
doses of 60–100 mg/kg/day prolonged survival and reduced
circulating leukemia cells in physiologically relevant mouse
models of CML-like myeloproliferative neoplasia and Ph+ B-
ALL induced by BCR-ABL1T315I (Figure 4) but had no effect on
hematopoiesis in normal mice (data not shown). Whereas
plasma concentrations of DCC-2036 exceeding 50 mM were
observed in recipient mice, after accounting for protein binding
(97%–99%), the active in vivo drug concentrations were in the
range of 100–1000 nM (data not shown). Tested against primary
patient cells in vitro, DCC-2036 suppressed Ph+ myeloid colony
formation and inhibited BCR-ABL1T315I kinase activity and phos-
phorylation of STAT5 and CrkL at these concentrations but did
not significantly inhibit growth of normal BM progenitors at
concentrations up to 2 mM (Figure 5A). Together, these results
demonstrate a differential inhibitory effect of DCC-2036 against
BCR-ABL1-expressing versus normal hematopoietic cells at
clinically relevant concentrations.
Based on its composite properties and these positive preclin-
ical results, DCC-2036 was selected for clinical development.
Correlative studies from the phase 1 clinical trial of DCC-2036
have demonstrated sustained inhibition of phospho-BCR-
ABL1, phospho-STAT5, and phospho-CrkL in patients with
refractory CML. In summary, DCC-2036 represents a potential
therapeutic option for patients with Ph+ leukemia who haveCancer Cell 19, 556–568, April 12, 2011 ª2011 Elsevier Inc. 565
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Inhibition of BCR-ABL1 T315I by DCC-2036relapsed on or are refractory to conventional TKIs. Exploiting the
diversity of switch-control mechanisms among different kinases
is a promising strategy to developmolecularly targeted therapies
for hematologic neoplasms, solid tumors, and nonmalignant
diseases.
EXPERIMENTAL PROCEDURES
Tyrosine Kinase Expression, Purification, Crystallography,
and Kinase Assays
His-tagged ABL1 kinase domain proteins were overexpressed in Sf9 cells via
a baculovirus vector, and unphosphorylated and phosphorylated proteins
purified by sequential Hi-Trap Ni and POROS HQ chromatography. Crystals
of ABL1-inhibitor complexes were grown by vapor diffusion and diffraction
data obtained with the beam source, data collection, and refinement statistics
provided in Table S2. Purified ABL1 kinases were assayed by quantitation of
ADP production by coupling with the pyruvate kinase/lactate dehydrogenase
system (Schindler et al., 2000). Detailed protein methods are provided in
Supplemental Experimental Procedures.
Cell Proliferation Assays
Ba/F3 cells (33 103 cells/well) or primary Ph+ leukemia cells (53 104 cells/well)
were plated in triplicate in 96-well plates containing test compounds. After
72 hr, viable cells were quantified by resazurin (O’Brien et al., 2000) or MTT
(Roumiantsev et al., 2002) assay as described. Results represent an average
of at least three independent experiments.
Immunoblotting Assays
Ba/F3 cells (2 3 106) expressing native or BCR-ABL1T315I were incubated for
6 hr in media containing test compounds, then lysed in RIPA buffer containing
protease inhibitors (Pierce, Rockford, IL, USA). In the case of Ba/F3 cells iso-
lated from allografted mice or primary human leukemia samples, mononuclear
cells were isolated by centrifugation through Ficoll-Hypaque and cell pellets
solubilized by direct boiling in NuPAGE LDS sample buffer (Invitrogen). Protein
was quantitated by the Pierce 660 nm Protein Assay Reagent, equal protein
amounts loaded onto NuPAGE 5%–15% gradient polyacrylamide gels, and
transferred to nitrocellulose membranes (Invitrogen LC2001) by electroblot-
ting. Blots were probed using phospho-specific antibodies, and bands were
detected using ECL Plus (GE Healthcare, Piscataway, NJ, USA) and a Molec-
ular Devices Storm 840 phosphorimager in fluorescence detection mode.
Band intensities were quantified using ImageQuant software and normalized
for loading differences based on eIF4E content. Blots were stripped and re-
probed with the corresponding total antibodies. Antibodies against pABL1,
pCrkL, ABL1, STAT5, and eIF4E were obtained from Cell Signaling Tech-
nology, pSTAT5 (pTyr694) from BD Biosciences, and CrkL from Santa Cruz
Biotechnology.
Allograft and Retroviral BM Transduction/Transplantation Mouse
Models of BCR-ABL1-Induced Leukemia
Retroviral stocks were generated and titered as previously described (Li et al.,
1999). Ba/F3 cells (13 106) transformed to IL-3 independence by transduction
with either BCR-ABL1native or BCR-ABL1T315I retrovirus were injected intrave-
nously into syngeneic Balb/c recipients, as described (Ilaria and Van Etten,
1995). Beginning day 3 postinjection, mice were treated with imatinib
(100 mg/kg in water twice daily via oral gavage) or with DCC-2036
(100 mg/kg in 0.5% CMC/1% Tween 80, once daily via oral gavage) or with
vehicle (0.5% CMC/1% Tween 80) alone. For induction of CML-like leukemia,
BM from male Balb/c donor mice was harvested 4 days after intravenous
administration of 150 mg/kg 5-FU, transduced with BCR-ABL1T315I retrovirus,
and 5 3 105 cells injected intravenously into sublethally irradiated (400 cGy)
Balb/c recipients. Beginning at day 5 posttransplant, cohorts were treated
once daily by oral gavage with vehicle alone, or DCC-2036 at 100 mg/kg.
For induction of B-ALL, BM from donors not pretreated with 5-FU was trans-
duced once with BCR-ABL1T315I retrovirus and 1 3 106 cells injected into
sublethally irradiated Balb/c recipients. Beginning at day 8 posttransplant,
cohorts were treated twice daily by oral gavage with vehicle alone, with
DCC-2036 at 60 mg/kg, with imatinib at 100 mg/kg (in water), or with dasatinib566 Cancer Cell 19, 556–568, April 12, 2011 ª2011 Elsevier Inc.at 10 mg/kg (in 80 mM citric acid [pH 3.1]). All mouse experiments were
approved by the Institutional Animal Use and Care Committee of Tufts Medical
Center.Pharmacodynamic Analysis of BCR-ABL1T315I Inhibition in Mice
by DCC-2036
Balb/c mice were inoculated with 1 3 106 Ba/F3 cells coexpressing BCR-
ABL1T315I and GFP as described above. On day 9 postinjection, leukemia-
bearingmicewere given a single dose of 100mg/kg DCC-2036 by oral gavage.
At the indicated times post-dose, pairs of mice were sacrificed, BM and spleen
harvested, and single-cell suspensions prepared. As a positive control,
cultured Ba/F3 cells expressing BCR-ABL1T315I were used, whereas the nega-
tive control was parental Ba/F3 cells starved of serum and IL-3 for 4 hr. For flow
cytometric analysis of pSTAT5 inhibition, cells were fixed with 2% paraformal-
dehyde, permeabilized with ice-cold 95%methanol with vortexing, and stored
at 20C overnight. For analysis, samples were rehydrated with 3 vol phos-
phate-buffered saline/0.5% BSA on ice for 1 hr, then incubated in FACS buffer
containing Alexa 647-conjugated anti-phospho-STAT5 antibody (Cell
Signaling Technology) in the dark for 30 min. Samples were washed once
and analyzed on a Cyan flow cytometer, gating on the GFP+ population. Inhi-
bition of pBCR-ABL1T315I was assessed by immunoblot analysis, as described
above.Inhibition of Primary CML Myeloid Colony Formation In Vitro
Primary BM cells from a patient with newly diagnosed CML and from a normal
individual, and PBmononuclear cells from a patient with CML-AP and imatinib
intolerance, were plated (5 3 104 cells/plate) in triplicate in methylcellulose
cultures (H5434; Stem Cell Technologies), either without or with kinase inhib-
itors at the indicated concentrations. Neither patient had detectable ABL1
kinase domain mutations. Colonies (CFU-GM) of >50 cell size were scored
at day 14.Collection of Patient Samples
Clinical samples were obtained with informed consent and under the approval
of the Institutional Review Board of Tufts Medical Center. Peripheral blood or
BM from patients or healthy subjects was separated by centrifugation in CPT
tubes (Becton Dickinson) for isolation of mononuclear cells.Inhibition of BCR-ABL1 Kinase Activity in Leukemic Cells In Vitro
Peripheral blood blasts from a patient with relapsed and refractory Ph+ B-ALL
and detectable T315I mutation (allele frequency 40%) were incubated over-
night (initial cell viability >90%) in IMDM supplemented with 100 mM 2-mecap-
toethanol and 0.5% BSA, and either without drug or with imatinib (1 mM) or
DCC-2036 (50, 200, and 1000 nM). After incubation, cells were lysed and
protein extracts subjected to immunoblot analysis as described above.
Peripheral blood mononuclear cells (7.5 3 105) from a patient with chronic-
phase CML and L298V mutation were incubated in varying concentrations of
DCC-2036 or DMSO for 3 hr, followed by lysis and immunoblot analysis.Pharmacodynamic Analysis of pSTAT5 and pCrkL Inhibition in CML
Cells In Vivo
After obtaining informed consent, peripheral blood leukocytes from patients
with relapsed/refractory CML were collected at the indicated times before
and after the oral dose of DCC-2036 on day 1 or 8 of therapy on a phase 1
dose-escalation clinical trial. Extracts from peripheral bloodmononuclear cells
were analyzed by immunoblotting.ACCESSION NUMBERS
Crystallographic coordinates have been deposited at the RCSB Protein Data
Bank under accession numbers 3QRK for the compound 1:ABL1native complex
(Figure S1), 3QRI for the DCC-2036:ABL1native complex (Figure S2A), and
3QRJ for the DCC-2036:ABL1T315 complex (Figure 2; Figure S2B).
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